Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: Efficacy and safety of nivolumab plus ipilimumab vs sunitinib for treatment-naïeve advanced or metastatic renal cell carcinoma, including IMDC risk and PD-L1 expression subgroups. ESMO 2017 Congress; abstract LBA5.
Klinisch bewijs binnen handbereik met behulp van AI
mei 2024 | Gynaecologische oncologie, Longoncologie, Maag-darm-leveroncologie, Uro-oncologie